EP1002121A1 - Methode de preparation de l-alaminol et d'amide de gamma-glutanylisopropyl et d'une souche de microorganisme du genre psendomonas - Google Patents

Methode de preparation de l-alaminol et d'amide de gamma-glutanylisopropyl et d'une souche de microorganisme du genre psendomonas

Info

Publication number
EP1002121A1
EP1002121A1 EP98947422A EP98947422A EP1002121A1 EP 1002121 A1 EP1002121 A1 EP 1002121A1 EP 98947422 A EP98947422 A EP 98947422A EP 98947422 A EP98947422 A EP 98947422A EP 1002121 A1 EP1002121 A1 EP 1002121A1
Authority
EP
European Patent Office
Prior art keywords
alaninol
microorganisms
isopropylamine
kie
ipa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98947422A
Other languages
German (de)
English (en)
Inventor
Susana Ivone DE AZEVEDO WÄSCH
Jan Rudolf Van Der Ploeg
Thomas Leisinger
Andreas Kiener
Klaus Heinzmann
Thomas Gilligan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lonza AG
Original Assignee
Lonza AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza AG filed Critical Lonza AG
Publication of EP1002121A1 publication Critical patent/EP1002121A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/001—Amines; Imines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids

Definitions

  • the invention relates to new microorganisms which are capable of growing with isopropylamine as the sole source of C and / or N, and to microorganisms which produce L-alaninol from isopropylamine and do not catabolize the latter.
  • the latter are used for a new process for the production of L-alaninol (S - (+) - 2-amino-l-propanol) starting from isopropylamine.
  • L-alaninol is an important intermediate for the production of pharmaceuticals, for example for the production of ofloxacin (J. Med. Chem 1997, 30, 2283-2286)
  • the object of the present invention was to provide a simple and inexpensive process for the preparation of L-alaninol.
  • microorganisms according to the invention are obtainable by the steps.
  • Microorganisms that are capable of growing on isopropylamine and L-alaninol as the only source of C and / or N can be selected and isolated from soil samples, sludge or wastewater, in particular contaminated soils and sewage sludge, using standard microbiological techniques.
  • the isolation is expediently carried out by enriching the desired microorganisms from a sample by selection with isopropylamine as the only C and / or N source.
  • selective enrichment with L-alaninol as the only C - and / or N source selected stable microorganisms which are capable of utilizing isopropylamine and L-alaninol as the only C and N source
  • the "wild stems" obtained in this way are then subjected to mutagenesis, the mutagenesis being able to be carried out according to methods known per se (JH Miller, Experiments in Molecular Genetics, Cold Spring Harbor Laboratory, 1972).
  • Appropriate mutation methods are the point mutation method, for example with the aid of mutagenic agents or UV radiation, the frameshift method, the deletion method or the transposon insertion method
  • microorganisms according to the invention are therefore preferably selected for isopropylamine, L-alaninol and L-alanine as the only C- and / or N source.
  • desired microorganisms can be recognized from the fact that they are no longer able to grow on isopropylamine and L-alaninol, but on L-alanine as the only C and / or N source. These strains are referred to below as "alaninol producers"
  • D-alanine L-2-amino-2-methylacetaldehyde, L- or D, L-lactic acid or their salts
  • pyruvate Both the "wild stems" and the "alaninol producers" preferably belong to the genus Pseudomonas, in particular to the species Pseudomonas sp Kie 171, Kie 171-B (DSM 1 1521) and Kie 171-B 1 (DSM 1 1629) are also included their functionally equivalent variants and mutants.
  • microorganisms Pseudomonas sp Kie 171-B were released on April 23, 1997, Kie-Bl (DSM 1 1629) on June 25, 1997 and Kie 171 (DSM 12360) on 05 08 1998 deposited with the German Collection for Microorganisms and Cell Cultures GmbH, Mascheroderweg lb, D-38124 Braunschweig, in accordance with the Budapest Treaty
  • “Functionally equivalent variants and mutants” are understood to mean microorganisms which are derived from the original organisms and which have the properties and functions which are essential to the invention. These variants and mutants can be accidentally formed, for example, by UV radiation
  • this strain could be similar to Pseudomonas citronellolis.
  • the microorganisms are usually cultured (attracted) in a medium customary for the specialist prior to the actual biotransformation.
  • the medium described in Table 1 can be used as the selection and growth medium.
  • IPA isopropylamine
  • Kie 171-B (DSM 11521) and Kie-B l (DSM 11629) and their functionally equivalent variants and mutants
  • the biotransformation can be carried out with resting cells (non-growing cells that no longer need a C and energy source) or with growing cells
  • Suitable media for the biotransformation are the commercially customary, for example low-molecular phosphate buffers, Hepes buffers and full media such as "Nutrient Yeast Broth” (NYB) or mineral salt media as described in Kulla et al, (Aren. Microbiol. 135, 1 (1983)) or in Table 1
  • the biotransformation is expediently carried out with a single or continuous addition of IPA such that the concentration of IPA does not exceed 10% by weight, preferably 1% by weight
  • the pH can range from 4 to 10, preferably from 5 to 9
  • Biotransformation is expediently carried out at a temperature of 10 to 50 ° C., preferably 20 to 40 ° C.
  • L-alaninol can be isolated by customary work-up methods, for example by distillation of the basic, cell-free fermentation broth
  • ⁇ -Glutamylisopropylamide is an important intermediate for the production of gluta-in-transport inhibitors (WO 91/12232).
  • Aerobic microorganisms which are able to utilize IPA as the only C and N source were enriched on minimal medium (Table 1) in the presence of 25 mM IPA as the only C source.
  • 100 ml of this medium were placed in 300 ml Erlenmeyer flasks and inoculated with different clear sludge samples (2 ml) from the LONZA AG clearing plant in Visp, Switzerland. The flasks were incubated at 30 ° C for 5 days. Then 1 ml of the medium was used to inoculate another flask with the fresh medium Flask was again incubated under the same conditions. In total, this enrichment cycle was repeated five times. The enriched bacteria were then spread on minimal medium with agar (15 g / 1) and 25 mM IPA to form individual colonies.
  • the isolated IPA-utilizing microorganisms were further selected under the same conditions for the ability to utilize L-alaninol as the only C source.
  • the strain Pseudomonas sp Kie-171 wild-type strain was finally isolated in this way
  • the growth of the strain Kie 171 was tested on various C sources (in each case 20 mM, pH 7.0) in 25 ml minimal medium. The growth was monitored by measuring the OD 650 . The results are described in Table 2. There was growth on the following C sources: isopropylamine, L-alaninol, L-alanine, D-alanine, L-lactate, D, L-lactate, propionic acid, propane-l, 2-diol, ethanolamine and propionic acid aldehyde.
  • Mutants for the production of L-alaninol from IPA should not be able to utilize either IPA or L-alaninol. They should only transform IPA into L-alaninol
  • Kie 171 was grown to 20 mM IPA to an OD f , 50 of 0.6 (exponential phase).
  • N-methyl-N '-nitro-N-nitrosoguanidine (MNNG) was suspended in a Strain Kie 171 [concentration of 0.5 ⁇ g / ⁇ l cells (2.5 ⁇ 10 cells / ml)] given in C-free medium after 30 minutes
  • E coli S17-1 ⁇ pir which contains the plasmid pUT mi-Tn5 with the kanamycin (Km) resistance gene, was conjugated to Pseudomonas sp Kie 171.
  • the donor strain E coli S17-1 ⁇ pir was conjugated to a fresh Luria bread ( LB) plate with 200 ⁇ g A picillin per ml grown at 37 ° C.
  • Pseudomonas sp Kie 171 was cultivated on an MM (minimal medium) plate (Table 1) with 20 mM IPA at 30 ° C.
  • E coli S17-1 ⁇ pir colony was used to inoculate 25 ml LB medium containing 200 ⁇ g / ml ampicillin and 50 ⁇ g / ml km. This culture was grown overnight at 150 rpm at 37 ° C. Pseudomonas sp Kie 171 was also used
  • the colonies subsequently obtained were tested for growth on various C sources (IPA, L-alaninol, L-alanine, L-lactate, L-alanine and L-glutamate) in the presence of 50 ⁇ g / ml km. This took place first on solid medium and then in liquid culture. Mutants that were unable to utilize IPA and L-alaninol were examined further. The mutant Kie 171-B1 was isolated, which grew neither on IPA nor on L-alaninol, but could still utilize L-alanine, L-lactate and L-alanine and L-glutamate.
  • C sources IPA, L-alaninol, L-alanine, L-lactate, L-alanine and L-glutamate
  • a 25 ml overnight pre-culture from Kie 171-B (DSM 11521) was used for the biotransformation of IPA to L-alaninol. This was grown on minimal medium with 20 mM L-glutamate and used to inoculate a culture of 250 ml in a 1 liter bottle of the same medium. After culturing Kie 171-B until the beginning of the exponential phase (OD 650 from 0.4 to 0.6), IPA (10 mM) was added. After an OD 650 of 1 to 1.3 had been reached, the culture was run at 4000 rpm for 15 min. centrifuged and the sediment washed twice with half the amount of culture medium without a C source.
  • the cells could then be taken up in the desired volume of minimal medium (Table 1) without a C source, so that 5 ml of a concentrated cell suspension (OD 6JO ⁇ 13) was obtained.
  • a concentrated cell suspension OD 6JO ⁇ 13
  • this culture of resting cells was shaken at 150 rpm at 30 ° C.
  • the samples were taken at various times (16 h, 25 h and 40 h) In both initial concentrations of IPA (10 mM and 20 mM) a final concentration of 7 mM L-alaninol was reached after the biotransformation. This corresponded to a yield of 37% and 59% respectively.
  • the rest was non-metabolized IPA
  • L-alaninol was derivatized with 2,3,4,6-tetra-O-acetyl-ß-D-glucopyranosyl isothiocyanate.
  • a Machereyl-Nagel NUCLEOSIL 120 3 C I8 AB column was used at 40 ° C Detection takes place at 250 nm
  • Pseudomonas sp Kie 171 -B 1 was used for this experiment. This strain was grown analogously to Example 4 on MM medium with glutamate and kanamycin. After cultivation to the exponential phase, 10 mM IPA was added for enzyme induction. This culture was added for a further 3 h at 30 ° C and 150 rpm shaken Then the cells were centrifuged, washed with MM medium and concentrated to an OD546 «13 25 ml of this cell suspension were then filled into 100 ml serum bottles, which were sealed with rubber stoppers

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un procédé biotechnologique qui permet de produire du L-alaninol, de formule (I), et un procédé qui permet de produire du η-glutamylisopropylamide, de formule (III), en utilisant des nouveaux micro-organismes capables soit de produire du L-alaninol à partir d'isopropylamine, soit d'utiliser l'isopropylamine comme unique source de C et de N.
EP98947422A 1997-08-08 1998-08-07 Methode de preparation de l-alaminol et d'amide de gamma-glutanylisopropyl et d'une souche de microorganisme du genre psendomonas Withdrawn EP1002121A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CH187697 1997-08-08
CH187697 1997-08-08
CH189797 1997-08-12
CH189797 1997-08-12
PCT/EP1998/005029 WO1999007199A2 (fr) 1997-08-08 1998-08-07 Methode de preparation de l-alaminol et d'amide de gamma-glutanylisopropyl et d'une souche de microorganisme du genre pseudomonas

Publications (1)

Publication Number Publication Date
EP1002121A1 true EP1002121A1 (fr) 2000-05-24

Family

ID=25688899

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98947422A Withdrawn EP1002121A1 (fr) 1997-08-08 1998-08-07 Methode de preparation de l-alaminol et d'amide de gamma-glutanylisopropyl et d'une souche de microorganisme du genre psendomonas

Country Status (4)

Country Link
EP (1) EP1002121A1 (fr)
JP (1) JP2001513321A (fr)
AU (1) AU9434798A (fr)
WO (1) WO1999007199A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001073038A2 (fr) * 2000-03-31 2001-10-04 Lonza Ag Procede de production de l-alaninol par voie biotechnologique
CA2706463A1 (fr) 2007-12-20 2009-07-02 Basf Se Procede de fabrication de (s)-2-amino-1-propanol (l-alaninol) a partir de (s)-1-methoxy-2-propylamine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8503666D0 (en) * 1985-02-13 1985-03-13 Shell Int Research Producing 4-(2-methoxyethyl)-phenylglycidyl ether
JPH01287064A (ja) * 1988-05-13 1989-11-17 Lion Corp 光学活性アミノプロパノール誘導体の製造方法
JPH02295970A (ja) * 1989-05-10 1990-12-06 Asahi Chem Ind Co Ltd 光学活性なプロパン―２―オール誘導体の製造法
WO1991012232A1 (fr) * 1990-02-06 1991-08-22 Australian Commercial Research & Development Limited Composes et procedes de traitement et de diagnostic du cancer
JPH06199747A (ja) * 1992-12-28 1994-07-19 Sumika Fine Kemu Kk Ｌ−アラニノールの製造方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9907199A3 *

Also Published As

Publication number Publication date
WO1999007199A2 (fr) 1999-02-18
JP2001513321A (ja) 2001-09-04
AU9434798A (en) 1999-03-01
WO1999007199A3 (fr) 1999-04-29

Similar Documents

Publication Publication Date Title
DE68925002T2 (de) Verfahren zur Herstellung von optisch-aktiven alpha-substituierten organischen Säuren und Mikroorganismen und Enzyme, die dafür verwendet werden.
DD274631A5 (de) Verfahren zur biologischen herstellung von amiden
DE3587230T2 (de) Enzymatisches verfahren.
DE2413963A1 (de) Verfahren zur herstellung von 2-ketol-gulonsaeure und deren salzen auf mikrobiologischem wege
SK278491B6 (en) Microorganism agrobacterium sp. and microbiological producing method for hydroxylated derivatives of pyrazine
DE3587212T2 (de) Enzyme.
DD232310A5 (de) Verfahren zur herstellung von l-carnitin
EP1151131A1 (fr) Procede de preparation d'un antibiotique d'acide a pseudomonique a l'aide d'une methode microbiologique
EP1002121A1 (fr) Methode de preparation de l-alaminol et d'amide de gamma-glutanylisopropyl et d'une souche de microorganisme du genre psendomonas
EP1352050B1 (fr) Procede microbiologique pour la production d'amides
Wang et al. Isolation of a benzoate-utilizing Pseudomonas strain from soil and production of catechol from benzoate by transpositional mutants
DE69322720T2 (de) Verfahren zur Herstellung von Biotin
EP1002122B1 (fr) Procede de fabrication d'amides
EP0584104A1 (fr) Procede d'obtention de dimethylamine-deshydrogenase ou de trimethylamine-deshydrogenase, deshydrogenases ainsi obtenues et leur utilisation
EP0556465B1 (fr) Procédé microbiologique pour la préparation d'acides hétérocycliques aromatiques hydroxylés
EP1018546B1 (fr) Micro-organismes produisant l'acide 5-aminolevulinique et procedes de production de cet acide a l'aide de ces micro-organismes
RU2292392C2 (ru) ШТАММ БАКТЕРИЙ Pseudomonas alcaligenes, ИСПОЛЬЗУЕМЫЙ ДЛЯ ОЧИСТКИ ПОЧВ, ГРУНТОВЫХ И ПОВЕРХНОСТНЫХ ВОД ОТ ТРИНИТРОТОЛУОЛА
DE69839248T2 (de) VERFAHREN FÜR DIE HERSTELLUNG VON INHIBITOREN DER HMG-CoA-REDUKTASE.
US5496715A (en) Process for preparing indigo
Singh et al. Evaluation of carbazole degradation by Enterobacter sp. isolated from hydrocarbon contaminated soil
JP4395005B2 (ja) 低重合度ε−ポリ−Ｌ−リジンを生産する菌株及びそれを用いた低重合度ε−ポリ−Ｌ−リジンの製造法
JPH08196288A (ja) 長鎖脂肪酸の製造法
JPH02227069A (ja) 細菌の培養法
DE10260456A1 (de) Mutanten des Bakterienstammes Delftia acidovorans MC1 und deren Verwendung zur Produktion von hochreinen R-Enantiomeren von 2-Phenoxypropionsäure-Derivaten
CA2297675A1 (fr) Methode de preparation de l-alaminol et d'amide de gamma-glutanylisopropyl et d'une souche de microorganisme du genre pseudomonas

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000119

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB IE IT LI NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GILLIGAN, THOMAS

Inventor name: HEINZMANN, KLAUS

Inventor name: KIENER, ANDREAS

Inventor name: LEISINGER, THOMAS

Inventor name: VAN DER PLOEG, JAN, RUDOLF

Inventor name: DE AZEVEDO WAESCH, SUSANA, IVONE

17Q First examination report despatched

Effective date: 20020503

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020914